Eli Lilly and Company opens new technology and innovation site in Hyderabad, India to enhance global operations.

Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...

Lilly has already taken 100 professionals at the Hyderabad facility and plans to expand the headcount to 1,500 over the next ...

Eli Lilly and Company has opened a technology and innovation center in, India. This strategic hub, covering 2.2 lakh sqft, ...

Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers’ first choice for patients with Type ...

Eli Lilly's Mounjaro shows significant cardiovascular benefits in a major trial enhancing treatment options for type 2 ...

Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival ...

Eli Lilly and Company (NYSE:LLY) is one of the Stocks With Huge Catalysts on the Horizon. On July 21, Eli Lilly and Company ...

A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin drug strategy.

Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...